Tetraphase CEO touts trou­bled an­tibi­ot­ic’s peak sales po­ten­tial; Copen­hagen wants to host the EMA

• Shares of Tetraphase Phar­ma­ceu­ti­cals $TTPH have dropped more than 90% off their high and the lead an­tibi­ot­ic failed a Phase III, but CEO Guy Mac­don­ald is still tout­ing er­ava­cy­cline’s com­mer­cial po­ten­tial. The an­tibi­ot­ic could earn $700 mil­lion a year, he told Reuters. “We just need the da­ta,” Mac­don­ald said. And how.

• Por­to­la $PT­LA says that the FDA doesn’t plan to hold an Ad­Comm meet­ing for be­trix­a­ban, their Fac­tor Xa in­hibitor an­ti­co­ag­u­lant. “Based on the APEX da­ta, we re­main con­fi­dent in the po­ten­tial for be­trix­a­ban to be ap­proved as the first an­ti­co­ag­u­lant for ex­tend­ed-du­ra­tion VTE pro­phy­lax­is in high-risk acute med­ical­ly ill pa­tients,” said John T. Cur­nutte, MD, PhD, ex­ec­u­tive vice pres­i­dent, re­search and de­vel­op­ment, at Por­to­la. Por­to­la was slammed last year when the FDA re­ject­ed its an­ti-an­ti­co­ag­u­lant an­dex­anet al­fa.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.